As the United Nations General Assembly's upcoming high-level meeting on antimicrobial resistance highlights, there is an urgent need to address blind spots in AMR test-to-treat data.
The lack of robust AMR test-to-treat data hampers effective decision-making and could jeopardize global health initiatives aimed at combating antimicrobial resistance.
Leaders must recognize that prioritizing AMR data is critical to devising effective strategies and policies that can yield substantial public health benefits.
With stakes rising in the fight against AMR, the focus must shift to improving access to and the quality of AMR test-to-treat information.
Collection
[
|
...
]